JOSE VASQUEZ

15.1K posts

JOSE VASQUEZ banner
JOSE VASQUEZ

JOSE VASQUEZ

@JAV2

Managing Partner @ LeverVenture | Backing Life Sciences & Deep Tech Founders | 20 Years Building Startup Ecosystems | Former JumpStart Chairman

San Juan, PR Se unió Şubat 2009
1.1K Siguiendo76.3K Seguidores
JOSE VASQUEZ
JOSE VASQUEZ@JAV2·
5/5 Recent client example: AI inventory optimization → 23% cost reduction in 60 days Secret: Spent 3 weeks on integration before touching ML Result: AI actually changes purchase orders automatically Integration > Intelligence
English
0
0
0
46
JOSE VASQUEZ
JOSE VASQUEZ@JAV2·
4/5 Quick test for your AI system: 🔄 Can it write back to your core systems? ⚡ Real-time sync or just batch exports? 👥 Are humans manually copying AI outputs? If you're failing these tests, you have an intelligence problem, not an AI problem
English
1
0
0
59
JOSE VASQUEZ
JOSE VASQUEZ@JAV2·
1/5 🧵 Your AI project isn't failing because of bad data or wrong models It's failing because of integration architecture Worked with 50+ companies on AI deployments. The pattern is always the same...
English
1
0
0
187
JOSE VASQUEZ
JOSE VASQUEZ@JAV2·
7/7 The bottom line: Life sciences investing in 2026 isn't about choosing biotech OR AI It's about finding founders who can execute at the intersection Technical fluency + domain expertise = non-negotiable What convergence trends are you tracking?
English
0
0
0
24
JOSE VASQUEZ
JOSE VASQUEZ@JAV2·
6/7 What this means for fund strategy: ❌ Pure-play biotech funds struggling ❌ Generalist AI funds missing domain expertise ✅ Hybrid approaches with technical + clinical diligence ✅ Co-investment with strategic partners (Sanofi, etc.)
English
1
0
0
37
JOSE VASQUEZ
JOSE VASQUEZ@JAV2·
1/7 🧵 Life Sciences VC in 2026: Why the old playbook isn't working anymore Just analyzed $270M+ in Q1 deals. The data shows a fundamental shift that most investors are missing...
English
1
0
0
147
JOSE VASQUEZ
JOSE VASQUEZ@JAV2·
6/7 🏆 Platform > single assets: Investors are prioritizing scalable technology platforms over one-shot drug candidates. Proprietary datasets + novel ML = defensible moats that pharma giants want to partner with.
English
1
0
1
30
JOSE VASQUEZ
JOSE VASQUEZ@JAV2·
1/7 🧵 The AI-biotech convergence is creating the biggest shift in life sciences investing we've seen in decades. Here's what the data is telling us about 2026 trends:
English
1
0
0
120
Carrie Rose
Carrie Rose@CarrieRosePR·
I’m looking to set up a small WhatsApp chat of a few other agency founders to support each other right now. None judgemental. No gossiping. Just support. I could do with someone to chat to tbh. Anyone fancy it?
Yorkshire and The Humber, England 🇬🇧 English
110
7
130
0